Merck (MRK) closed at $80.40 in the latest trading session, marking a -1.36% move from the prior day. This change lagged the S&P 500's 0.44% gain on the day. On the other hand, the Dow registered a ...

Patients taking the immunotherapy drug Keytruda (pembrolizumab) may now have the option to take it as a quick shot instead of ...

On September 15, 2025, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo revealed that the FDA granted Breakthrough Therapy ...

The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's ...

Three Motley Fool contributors believe they've found dirt cheap value stocks to buy right now. Here's why they picked Merck ...

FDA approves Keytruda Qlex, a subcutaneous injection version of the widely used cancer therapy Keytruda Patients can now ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...

Merck trades at a deep discount to peers with strong profitability, Keytruda-led growth, and a 3.99% yield despite near-term ...

Oh, they’ve got some good stuff in the, they’ve made a couple good acquisitions. The dividend seems safe. I think Rob Davis ...

Look at the data compiled by the industry association and other researchers, though, and it’s hard not to conclude that ...

Here's what you need to know about these three healthcare dividend stocks.

The cancer medication Keytruda is the world’s bestselling drug. But with lower-priced competition set to arrive as soon as 2028, Keytruda’s manufacturer, Merck, is on the brink of losing tens of ...